Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class ...
Iran has ranked among the world’s top three radiopharmaceutical producers, providing isotopes to domestic centres and ...
A Registrational Phase 2 clinical trial has been initiated for 64Cu-PSMA-I&T - a PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells PARIS, ...
PARIS, Oct. 15, 2025 (GLOBE NEWSWIRE) — Curium Group announced today that together with PeptiDream Inc. and PDRadiopharma Inc., a registrational Phase 2 clinical trial has been initiated in Japan for ...
The new £360,000 fee-for-service development contract is to develop Optimer® binders as targeted radiopharmaceuticals with potential applications in therapeutics. Aptamer retains rights for future ...
By rethinking operational models, radiopharma leaders can mitigate risks, increase efficiency and ensure reliable access to ...
CXC chemokine receptor 4 (CXCR4) is a receptor overexpressed in several tumor types and associated with tumor aggressiveness and risk of metastasis, resistance and recurrence. A novel PET ...
MedPage Today on MSN
Amyloid-Binding Radiotracer Spurs Hope for Better ATTR-CM Diagnosis
The resulting 124 I-evuzamitide (previously known as AT-01) has been shown to detect amyloidosis in organs like the heart, ...
The FDA has set a PDUFA target action date of March 29, 2026. “The development of LNTH-2501 underscores our commitment to expanding access to high-quality diagnostic solutions in oncology,” said Brian ...
The NDA submission is supported by data from two pivotal Phase 3 clinical trials, which evaluated MK-6240’s performance in detecting tau pathology in early Alzheimer’s disease. These studies met their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback